{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:38:12Z","timestamp":1790948292329,"version":"4.1.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Our objective was to identify recent CPGs for the diagnosis and management of DMD and summarize their characteristics and reliability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a scoping review of CPGs using MEDLINE, the Turning Research Into Practice (TRIP) database, Google Scholar, guidelines created by organizations, and other repositories to identify CPGs published in the last 5 years. Our protocol was drafted using the Preferred Reporting Items for Systematic Reviews and Meta-analyses for scoping reviews. To assess the reliability of the CPGs, we used all the domains included in the Appraisal of Guidelines Research and Evaluation II.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We selected three CPGs published or updated between 2015 and 2020. All the guidelines showed good or adequate methodological rigor but presented pitfalls in stakeholder involvement and applicability domains. Recommendations were coherent across CPGs on steroid treatment, except for minor differences in dosing regimens. However, the recommendations were different for new drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>There is a need for current and reliable CPGs that develop broad topics on the management of DMD and consider the challenges of developing recommendations for RDs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1260610","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T12:50:53Z","timestamp":1704459053000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical practice guidelines for the diagnosis and management of Duchenne muscular dystrophy: a scoping review"],"prefix":"10.3389","volume":"14","author":[{"given":"Marco","family":"Malaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Rodriguez-Calienes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian A.","family":"Chavez-Ecos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrely","family":"Huerta-Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Alvarado-Gamarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Cabanillas-Lazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Moran-Ballon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Vel\u00e1squez-Rimachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Martinez-Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Alva-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat Rev Dis Prim."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/FPHYS.2023.1183101","article-title":"Duchenne muscular dystrophy: disease mechanism and therapeutic strategies","author":"Bez Batti Angulski","year":"2023","journal-title":"Front Physiol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/S13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis","author":"Crisafulli","year":"2020","journal-title":"Orphanet J Rare Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12874-019-0713-0\/PEER-REVIEW","article-title":"Strategies for eliciting and synthesizing evidence for guidelines in rare diseases","volume":"19","author":"Pai","year":"2019","journal-title":"BMC Med Res Methodol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/S13023-017-0755-5","article-title":"An overview of the impact of rare disease characteristics on research methodology","author":"Whicher","year":"2018","journal-title":"Orphanet J Rare Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/J.JCLINEPI.2021.03.034","article-title":"Getting trustworthy guidelines into the hands of decision-makers and supporting their consideration of contextual factors for implementation globally: recommendation mapping of COVID-19 guidelines","volume":"135","author":"Lotfi","year":"2021","journal-title":"J Clin Epidemiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/S41431-017-0008-Z","article-title":"The international rare diseases research consortium: policies and guidelines to maximize impact","volume":"25","author":"Lochm\u00fcller","year":"2017","journal-title":"Eur J Hum Genet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12874-018-0611-X\/TABLES\/1","article-title":"Systematic review or scoping review? guidance for authors when choosing between a systematic or scoping review approach","volume":"18","author":"Munn","year":"2018","journal-title":"BMC Med Res Methodol."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/BMJGAST-2020-000592","article-title":"Scoping review of clinical practice guidelines on the management of benign liver tumours","author":"Haring","year":"2021","journal-title":"BMJ Open Gastroenterol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/BJOPHTHALMOL-2021-319504","article-title":"Intravitreal antivascular endothelial growth factor in diabetic macular oedema: scoping review of clinical practice guidelines recommendations","volume":"107","author":"Vargas-Peirano","year":"2023","journal-title":"Br J Ophthalmol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/FMED.2022.821871","article-title":"Treatment guidelines for atopic dermatitis since the approval of dupilumab: a systematic review and quality appraisal using AGREE-II","author":"Ghazal","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"B13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"E839","DOI":"10.1503\/CMAJ.090449","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"CMAJ : Canad Med Assoc J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"5450","DOI":"10.1080\/09638288.2021.1936221","article-title":"Development of clinical practice guidelines for allied health and nursing assessment and management of Duchenne muscular dystrophy","volume":"44","author":"Davidson","year":"2022","journal-title":"Disabil Rehabil."},{"key":"B16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1212\/WNL.0000000000002337","article-title":"Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the guideline development subcommittee of the American academy of neurology","volume":"86","author":"Gloss","year":"2016","journal-title":"Neurology."},{"key":"B17","unstructured":"2023"},{"key":"B18","unstructured":"2014"},{"key":"B19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/J.JPEDS.2018.10.043","article-title":"Evidence-based consensus and systematic review on reducing the time to diagnosis of duchenne muscular dystrophy","volume":"204","author":"Aartsma-Rus","year":"2019","journal-title":"J Pediatr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/J.NRL.2018.01.001","article-title":"Consensus on the diagnosis, treatment and follow-up of patients with Duchenne muscular dystrophy","volume":"34","author":"Nascimento Osorio","year":"2019","journal-title":"Neurologia."},{"key":"B21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1590\/0004-282X20170112","article-title":"Brazilian consensus on Duchenne muscular dystrophy: part 1: diagnosis, steroid therapy and perspectives","volume":"75","author":"Araujo","year":"2017","journal-title":"Arq Neuropsiquiatr."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/FPED.2021.629549","article-title":"Consensus statement on the management of Duchenne muscular dystrophy in Saudi Arabia During the coronavirus disease 2019 pandemic","author":"Bamaga","year":"2021","journal-title":"Front Pediatr."},{"key":"B23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/S00115-020-01019-3","volume":"92","author":"Bernert","year":"2021","journal-title":"Nervenarzt."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41431-020-0643-7","article-title":"EMQN best practice guidelines for genetic testing in dystrophinopathies","volume":"28","author":"Fratter","year":"2020","journal-title":"Euro J Hum Genetics."},{"key":"B25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2217\/NMT-2019-0002","article-title":"Current management of Duchenne muscular dystrophy in the Middle East: expert report","volume":"9","author":"Jumah M","year":"2019","journal-title":"Neurodegener Dis Manag."},{"key":"B26","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3233\/JND-200609","article-title":"Adult North Star Network (ANSN): consensus guideline for the standard of care of adults with duchenne muscular dystrophy","volume":"8","author":"Quinlivan","year":"2021","journal-title":"J Neuromuscul Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12916-015-0436-Y\/FIGURES\/1","article-title":"Trustworthy guidelines - excellent; customized care tools - even better","volume":"13","author":"Elwyn","year":"2015","journal-title":"BMC Med."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.I2016","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.JCLINEPI.2020.09.037","article-title":"Developing trustworthy recommendations as part of an urgent response (1-2 weeks): a GRADE concept paper","volume":"129","author":"Akl","year":"2021","journal-title":"J Clin Epidemiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/BMJ.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.VHRI.2017.10.003","article-title":"Cost-Effectiveness analysis of diagnosis of duchenne\/becker muscular dystrophy in Colombia","volume":"17","author":"Atehort\u00faa","year":"2018","journal-title":"Value Health Reg Issues."},{"key":"B32","author":"Esp\u00edn","year":"2011","journal-title":"Experiences and Impact of European Risk-Sharing Schemes Focusing on Oncology Medicines"},{"key":"B33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2217\/CER.12.7","article-title":"Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement","volume":"1","author":"Deverka","year":"2012","journal-title":"J Comp Eff Res."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1186\/S13023-021-01758-9","article-title":"Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?","author":"Kourakis","year":"2021","journal-title":"Orphanet J Rare Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1183\/09031936.06.00125404","article-title":"Corticosteroid effects on cell signalling","volume":"27","author":"Barnes","year":"2006","journal-title":"Euro Res J."},{"key":"B36","unstructured":""},{"key":"B37","author":"Gronseth","year":"2017","journal-title":"2017 Edition Clinical Practice Guideline Process Manual Prepared by"},{"key":"B38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/J.JCLINEPI.2017.01.017","article-title":"GRADE equity guidelines 2: considering health equity in GRADE guideline development: equity extension of the guideline development checklist","volume":"90","author":"Akl","year":"2017","journal-title":"J Clin Epidemiol."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0025153","article-title":"Conflict of interest in clinical practice guideline development: a systematic review","author":"Norris","year":"2011","journal-title":"PLoS One."},{"key":"B40","doi-asserted-by":"publisher","first-page":"E49","DOI":"10.1503\/CMAJ.200651\/TAB-RELATED-CONTENT","article-title":"Managing conflicts of interest in the development of health guidelines","volume":"193","author":"Traversy","year":"2021","journal-title":"CMAJ."},{"key":"B41","article-title":"Conflict of interest in medical research, education, and practice","year":"2009","journal-title":"Conflict of Interest in Medical Research, Education, and Practice"},{"key":"B42","unstructured":"Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study\n            BelloL\n            Gordish-DressmanH\n            MorgenrothLP\n            HenricsonEK\n            DuongT\n            HoffmanEP\n          263117502015"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jama.2022.4315","article-title":"Effect of different corticosteroid dosing regimens on clinical outcomes in boys with duchenne muscular dystrophy: a randomized clinical trial","volume":"327","author":"Guglieri","year":"2022","journal-title":"JAMA."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/JAMANEUROL.2022.2480","article-title":"Efficacy and safety of vamorolone vs placebo and prednisone among boys with duchenne muscular dystrophy: a randomized clinical trial","volume":"79","author":"Guglieri","year":"2022","journal-title":"JAMA Neurol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/J.NMD.2014.11.011","article-title":"European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene","volume":"25","author":"Haas","year":"2015","journal-title":"Neuromuscul Disord."},{"key":"B46","unstructured":""},{"key":"B47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1089\/NAT.2018.0756","article-title":"a sequel to the Eteplirsen Saga: Eteplirsen is approved in the United States but was not approved in Europe","volume":"29","author":"Aartsma-Rus","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/MUS.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"Bushby","year":"2014","journal-title":"Muscle Nerve."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet."},{"key":"B50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2217\/CER-2021-0196\/SUPPL_FILE\/CER-11-139-S2.PDF","article-title":"Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients","volume":"11","author":"McDonald","year":"2022","journal-title":"J Comp Eff Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1007\/S00415-023-11687-1","article-title":"Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015\u20132022): 2022 interim analysis","volume":"270","author":"Mercuri","year":"2023","journal-title":"J Neurol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/JNNP-2014-309405","article-title":"The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials","volume":"87","author":"Ricotti","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e1058463","DOI":"10.1080\/21675511.2015.1058463","article-title":"Developing methodology for the creation of clinical practice guidelines for rare diseases: a report from RARE-Bestpractices","volume":"3","author":"Pai","year":"2015","journal-title":"Rare Diseases."},{"key":"B54","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/BMJ.39490.551019.BE","article-title":"What is \u201cquality of evidence\u201d and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/IJERPH20064732","article-title":"Enhancing equitable access to rare disease diagnosis and treatment around the world: a review of evidence, policies, and challenges","author":"Adachi","year":"2023","journal-title":"Int J Environ Res Public Health."},{"key":"B56","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1542\/PEDS.2018-0333D","article-title":"Rehabilitation management of the patient with duchenne muscular dystrophy","volume":"142","author":"Case","year":"2018","journal-title":"Pediatrics."},{"key":"B57","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jclinepi.2017.08.001","article-title":"GRADE equity guidelines 4: considering health equity in GRADE guideline development: evidence to decision process","volume":"90","author":"Pottie","year":"2017","journal-title":"J Clin Epidemiol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1260610\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T12:50:57Z","timestamp":1704459057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1260610\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":57,"alternative-id":["10.3389\/fneur.2023.1260610"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1260610","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]},"article-number":"1260610"}}